FIELD OF INVENTION [0002] The present invention relates to isoxazoloanthrones and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to isoxazoloanthrone compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

BACKGROUND [0003] Hepatitis C virus (HCV) infection is a global human health problem with approximately 150,000 new reported cases each year in the United States alone. HCV is a single stranded RNA virus, which is the etiological agent identified in most cases of non-A, non-B post-transfusion and post-transplant hepatitis and is a common cause of acute sporadic hepatitis (Choo et al., Science 244: 359,1989 ; Kuo et al., Science 244: 362,1989 ; and Alter et al., in Current Perspective in Hepatology, p. 83,1989). It is estimated that more than 50% of patients infected with HCV become chronically infected and 20% of those develop cirrhosis of the liver within 20 years (Davis et al., New Engl. J. Med. 321: 1501,1989 ; Alter et al., in Current Perspective in Hepatology, p. 83,1989 ; Alter et al., New Engl. J. Med. 327: 1899, 1992; and Dienstag Gastroenterology 85: 430,1983). Moreover, the only therapy available for treatment of HCV infection is interferon-a (INTRON° A, PEG-INTRON'g'A, Schering- Plough; ROFERON-AQ', PEGASys@, Roche). Most patients are unresponsive, however, and among the responders, there is a high recurrence rate within 6-12 months after cessation of treatment (Liang et al., J. Med. Virol. 40: 69,1993). Ribavirin, a guanosine analog with broad spectrum activity against many RNA and DNA viruses, has been shown in clinical trials to be effective against chronic HCV infection when used in combination with interferon-a (see, e. g.,

Poynard et al., Lancet 352: 1426-1432,1998 ; Reichard et al., Lancet 351: 83-87,1998), and this combination therapy has been recently approved (REBETRON, Schering-Plough; see also Fried et al., 2002, N. Engl. J. Med. 347: 975-982). However, the response rate is still at or below 50%. Therefore, additional compounds for treatment and prevention of HCV infection are needed.

SUMMARY [0004] In one aspect, the present invention provides compounds and compositions that are potent inhibitors of Hepatitis C virus ("HCV") replication and/or proliferation. In one embodiment, the compounds of the invention have the formula:

wherein.--'and-,"are independently selected to be a single bond or a double bond; [0005] Xl and X2 are independently selected from the group consisting of O, N, NR8, S, SO, SO2, and CR9Rio wherein R8 is H, lower alkyl, cycloalky, aryl, alkylcarbonyl, or arylcarbonyl, and Rg and RIO are independently selected from the group consisting of H and lower alkyl ; and [0006] Rl, R2, R3, R4, R5, R6, and R7 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, nitro, amino, alkoxyl, aryloxyl, aralkoxyl, alkylcarbamido, arylcarbamido, dialkylcarbamido, diarylcarbamido, alkylarylcarbamido, alkylthiocarbamido, arylthiocarbamido, dialkylthiocarbamido, diarylthiocarbamido, alkylarylthiocarbamidb, alkylamino, arylamino, dialkylamino, diarylamino, arylalkylamino, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, dialkylaminocarbonyl, diarylaminocarbonyl, arylalkylamino-carbonyl, alkylcarbonyloxy, arylcarbonyloxy, carboxyl, alkoxycarbonyl, aryloxycarbonyl, sulfo, alkylsulfonylamido, arylsulfonylarnido, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl and heteroaryl;

[0007] with the proviso that when sS§$ and v are both double bonds, X, is N, X2 is O, and R2, R4, R5, R6, and R7 are H, then (a) if R3 is aziridine, then Rs cannot be H, Br, Cl, or Me; (b) if R3 is Br, then Rl cannot be Me or OH; and (c) both R3 and Rl cannot be H, Br, Cl, OPh, or p-chlorophenoxy.

[0008] The compounds of the invention are potent inhibitors of HCV replication and/or proliferation. Accordingly, in still another aspect, the present invention provides methods of inhibiting HCV replication and/or proliferation, comprising contacting a Hepatitis C virion with an amount of a compound or composition of the invention effective to inhibit its replication or proliferation. The methods may be practiced either in vitro or in vivo, and may be used as a therapeutic approach towards the treatment and/or prevention of HCV infections.

[0009] In a another aspect, the present invention provides methods of treating and/or preventing HCV infections. The methods generally involve administering to a subject that has an HCV infection or that is at risk of developing an HCV infection an amount of a compound or composition of the invention effective to treat or prevent the HCV infection. The method may be practiced in animals in veterinary contexts or in humans.

DETAILED DESCRIPTION I. Definitions [0010] Unless otherwise stated, the following terms used in this application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms"a,""an"and"the"include plural referents unless the context clearly dictates otherwise. Definition of standard chemistry terms may be found in reference works, including Carey and Sundberg (1992)"Advanced Organic Chemistry 3d Ed. "Vols. A and B, Plenum Press, New York. The practice of the present invention will employ, unless otherwise indicated, conventional methods of mass spectroscopy, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology, within the skill of the art.

[0011] As used herein, the following terms are intended to have the following meanings: [0012]"Alkyl,"by itself or as part of another substituent, refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the

removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne.

Typical alkyl groups include, but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-1-yl, propan-2-yl, cyclopropan-1-yl, prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), cycloprop-1-en-1-yl ; cycloprop-2-en-1-yl, prop-1-yn-1-yl, prop-2-yn-1-yl, etc. ; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-1-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1, 3-dien-1-yl, buta-1, 3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1, 3-dien-1-yl, but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc. ; and the like.

[0013] The term"alkyl"is specifically intended to include groups having any degree or level of saturation, i. e. , groups having exclusively single carbon-carbon bonds, groups having one or more double carbon-carbon bonds, groups having one or more triple carbon-carbon bonds and groups having mixtures of single, double and triple carbon-carbon bonds. Where a specific level of saturation is intended, the expressions"alkanyl,""alkenyl,"and"alkynyl"are used. Preferably, an alkyl. group comprises from 1 to 15 carbon atoms (CI-CI5 alkyl), more preferably from 1 tolO carbon atoms (Cl-C, 0 alkyl) and even more preferably from 1 to 6 carbon atoms (Cl-C6 alkyl or lower alkyl).

[0014]"Alkanyl,"by itself or as part of another substituent, refers to a saturated branched, straight-chain or cyclic alkyl radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane. Typical alkanyl groups include, but are not limited to, methanyl; ethanyl; propanyls such as propan-1-yl, propan-2-yl (isopropyl), cyclopropan-1-yl, etc.; butanyls such as butan-1-yl, butan-2-yl (sec-butyl), 2-methyl-propan-1-yl (isobutyl), 2-methyl-propan-2-yl (t-butyl), cyclobutan-1-yl, etc. ; and the like.

[0015]"Alkenyl,"by itself or as part of another substituent, refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene.

The group may be in either the cis or trans conformation about the double bond (s). Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-1-en-1-yl, prop-1-en-2-yl, prop-2-en-1-yl (allyl), prop-2-en-2-yl, cycloprop-1-en-1-yl ;

cycloprop-2-en-1-yl ; butenyls such as but-1-en-1-yl, but-1-en-2-yl, 2-methyl-prop-1-en-1-yl, but-2-en-1-yl, but-2-en-1-yl, but-2-en-2-yl, buta-1, 3-dien-1-yl, buta-1, 3-dien-2-yl, cyclobut-1-en-1-yl, cyclobut-1-en-3-yl, cyclobuta-1, 3-dien-1-yl, etc. ; and the like.

[0016]"Alkynyl,"by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne.

Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop-1-yn-1-yl, prop-2-yn-1-yl, etc.; butynyls such as but-1-yn-1-yl, but-1-yn-3-yl, but-3-yn-1-yl, etc. ; and the like.

[00171"Alkyldiyl"by itself or as part of another substituent refers to a saturated or unsaturated, branched, straight-chain or cyclic divalent hydrocarbon group derived by the removal of one hydrogen atom from each of two different carbon atoms of a parent alkane, alkene or alkyne, or by the removal of two hydrogen atoms from a single carbon atom of a parent alkane, alkene or alkyne. The two monovalent radical centers or each valency of the divalent radical center can form bonds with the same or different atoms. Typical alkyldiyl groups include, but are not limited to, methandiyl; ethyldiyls such as ethan-1,1-diyl, ethan-1, 2-diyl, ethen-1,1-diyl, ethen-1, 2-diyl; propyldiyls such as propan-1,1-diyl, propan-1, 2-diyl, propan-2,2-diyl, propan-1, 3-diyl, cyclopropan-l, l-diyl, cyclopropan-1, 2-diyl, prop-1-en-1, 1-diyl, prop-1-en-1, 2-diyl, prop-2-en-1, 2-diyl, prop-1-en-1, 3-diyl, cycloprop-1-en-1, 2-diyl, cycloprop-2-en-1, 2-diyl, cycloprop-2-en-1, 1-diyl, prop-1-yn-1, 3-diyl, etc.; butyldiyls such as, butan-1,1-diyl, butan-1, 2-diyl, butan-1, 3-diyl, butan-1, 4-diyl, butan-2,2-diyl, 2-methyl-propan-1, 1-diyl, 2-methyl-propan-1, 2-diyl, cyclobutan-1, 1-diyl ; cyclobutan-1, 2-diyl, cyclobutan-1, 3-diyl, but-1-en-1, 1-diyl, but-1-en-1, 2-diyl, but-1-en-1, 3-diyl, but-1-en-1, 4-diyl, 2-methyl-prop-1-en-1, 1-diyl, 2-methanylidene-propan-1, 1-diyl, buta-1, 3-dien-1, 1-diyl, buta-1,3-dien-1, 2-diyl, buta-1,3-dien-1, 3-diyl, buta-1,3-dien-1, 4-diyl, cyclobut-1-en-1, 2-diyl, cyclobut-1-en-1, 3-diyl, cyclobut-2-en-1,2-diyl, cyclobuta-1,3-dien-1, 2-diyl, cyclobuta-1,3-dien-1, 3-diyl, but-1-yn-1, 3-diyl, but-1-yn-1, 4-diyl, buta-1, 3-din-1, 4-diyl, etc.; and the like. Where specific levels of saturation are intended, the nomenclature alkanyldiyl, alkenyldiyl and/or alkynyldiyl is used. Where it is specifically intended that the two valencies are on the same carbon atom, the nomenclature"alkylidene"is used. In preferred embodiments, the alkyldiyl group comprises from 1 to 6 carbon atoms (C1-C6 alkyldiyl). Also preferred are saturated acyclic

alkanyldiyl groups in which the radical centers are at the terminal carbons, e. g. , methandiyl (methano) ; ethan-1, 2-diyl (ethano); propan-1, 3-diyl (propano) ; butan-1, 4-diyl (butano); and the like (also referred to as alkylenos, defined infra).

[0018]"Alkyleno,"by itself or as part of another substituent, refers to a straight-chain saturated or unsaturated alkyldiyl group having two terminal monovalent radical centers derived by the removal of one hydrogen atom from each of the two terminal carbon atoms of straight-chain parent alkane, alkene or alkyne. The locant of a double bond or triple bond, if present, in a particular alkyleno is indicated in square brackets. Typical alkyleno groups include, but are not limited to, methano ; ethylenos such as ethano, etheno, ethyno; propylenos such as propano, prop [l] eno, propa [1, 2] dieno, prop [l] yno, etc.; butylenos such as butano, but [l] eno, but [2] eno, buta [1, 3] dieno, but [l] yno, but [2] yno, buta [1, 3] diyno, etc.; and the like.

Where specific levels of saturation are intended, the nomenclature alkano, alkeno and/or alkyno is used. In preferred embodiments, the alkyleno group is (C1-C6) or (C1-C3) alkyleno.

Also preferred are straight-chain saturated alkano groups, e. g., methano, ethano, propano, butano, and the like.

[0019]"Alkoxy,"by itself or as part of another substituent, refers to a radical of the formula-OR, where R is an alkyl or cycloalkyl group as defined herein. Representative examples alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, cyclopropyloxy, cyclopentyloxy, cyclohexyloxy and the like.

[0020]"Alkoxycarbonyl,"by itself or as part of another substituent, refers to a radical of the formula-C (O)-alkoxy, where alkoxy is as defined herein.

[0021]"Alkylthio,"by itself or as part of another substituent, refers to a radical of the formula-SR, where R is an alkyl or cycloalkyl group as defined herein. Representative examples of Alkylthio groups include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, butylthio tert-butylthio, cyclopropylthio, cyclopentylthio, cyclohexylthio, and the like.

[0022]"Arvl,"by itself or as part of another substituent, refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system, as defined herein. Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like. Preferably, an aryl group comprises from 6 to 20 carbon atoms (C6-C20 aryl), more preferably from 6 to 15 carbon atoms (C6-C, s aryl) and even more preferably from 6 to 10 carbon atoms (C6-C10 aryl).

[0023]"Arylalkyl,"by itself or as part of another substituent, refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl group as, as defined herein. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2-naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like. Where specific alkyl moieties are intended, the nomenclature arylalkanyl, arylalkenyl and/or arylalkynyl is used. Preferably, an arylalkyl group is (C6-C3o) arylalkyl, e. g. , the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C,-C, 0) alkyl and the aryl moiety is (C6-C20) aryl, more preferably, an arylalkyl group is (C6-C20) arylalkyl, e. g. , the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (CI-C8) alkyl and the aryl moiety is (C6-C, 2) aryl, and even more preferably, an arylalkyl group is (C6-Css) arylalkyl, e. g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is (C-C) alkyl and the aryl moiety is (C6-C, o) aryl.

[0024]"Aryloxv,"by itself or as part of another substituent, refers to a radical of the formula-O-aryl, where aryl is as defined herein.

[0025]"Arylalkvloxy, by itself or as part of another substituent, refers to a radical of the formula-O-arylalkyl, where arylalkyl is as defined herein.

[0026]"Aryloxvcarbonyl,"by itself or as part of another substituent, refers to a radical of the formula-C (O)-O-aryl, where aryl is as defined herein.

[0027]"Carbamoyl,"by itself or as part of another substituent, refers to a radical of the formula-C (O) NR'R", where R'and R"are each, independently of one another, selected from the group consisting of hydrogen, alkyl and cycloalkyl as defined herein, or alternatively, R' and R", taken together with the nitrogen atom to which they are bonded, form a 5-, 6-or 7- membered cycloheteroalkyl ring as defined herein, which may optionally include from 1 to 4 of the same or different additional heteroatoms selected from the group consisting of O, S and N.

[0028]"Compounds of the invention"refers to compounds encompassed by the various descriptions and structural formulae disclosed herein. The compounds of the invention may be identified by either their chemical structure and/or chemical name. When the chemical structure and chemical name conflict, the chemical structure is determinative of the identity of the compound. The compounds of the invention may contain one or more chiral centers and/or double bonds and therefore may exist as stereoisomers, such as double-bond isomers (i. e. , geometric isomers), rotamers, enantiomers or diastereomers. Accordingly, when stereochemistry at chiral centers is not specified, the chemical structures depicted herein encompass all possible configurations at those chiral centers including the stereoisomerically pure form (e. g., geometrically pure, enantiomerically pure or diastereomerically pure) and enantiomeric and stereoisomeric mixtures. Enantiomeric and stereoisomeric mixtures can be resolved into their component enantiomers or stereoisomers using separation techniques or chiral synthesis techniques well known to the skilled artisan. The compounds of the invention may also exist in several tautomeric forms including the enol form, the keto form and mixtures thereof. Accordingly, the chemical structures depicted herein encompass all possible tautomeric forms of the illustrated compounds. The compounds of the invention may also include isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass conventionally found in nature. Examples of isotopes that may be incorporated into the compounds of the invention include, but are not limited to, 2H, 3H, l lC, 3C, 14C, 15N, 18O, 170, 3lp, 32p, 35S, I8F and 36CI. Compounds of the invention may exist in unsolvated forms as well as solvated forms, including hydrated forms and as N-oxides. In

general, the hydrated, solvated and N-oxide forms are within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

[0029]"Cycloalkyl,"by itself or as part of another substituent, refers to a saturated or unsaturated cyclic alkyl radical, as defined herein. Where a specific level of saturation is intended, the nomenclature"cycloalkanyl"or"cycloalkenyl"is used. Typical cycloalkyl groups include, but are not limited to, groups derived from cyclopropane, cyclobutane, cyclopentane, cyclohexane, and the like. Preferably, the cycloalkyl group comprises from 3 to 10 ring atoms (Cs-Cio cycloalkyi) and more preferably from 3 to 7 ring atoms (C3-C7 cycloalkyl).

[0030]"Cvcloheteroalkvl."by itself or as part of another substituent, refers to a saturated or unsaturated cyclic alkyl radical in which one or more carbon atoms (and optionally any associated hydrogen atoms) are independently replaced with the same or different heteroatom.

Typical heteroatoms to replace the carbon atom (s) include, but are not limited to, N, P, O, S, Si, etc. Where a specific level of saturation is intended, the nomenclature "cycloheteroalkanyl"or"cycloheteroalkenyl"is used. Typical cycloheteroalkyl groups include, but are not limited to, groups derived from epoxides, azirines, thiiranes, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidone, quinuclidine, and the like. Preferably, the cycloheteroalkyl group comprises from 3 to 10 ring atoms (3-10 membered cycloheteroalkyl) and more preferably from 5 to 7 ring atoms (5-7 membered cycloheteroalkyl).

[0031] A cycloheteroalkyl group may be substituted at a heteroatom, for example, a nitrogen atom, with a lower alkyl group. As specific examples, N-methyl-imidazolidinyl, N-methyl-morpholinyl, N-methyl-piperazinyl, N-methyl-piperidinyl, N-methyl-pyrazolidinyl and N-methyl-pyrrolidinyl are included within the definition of"cycloheteroalkyl."A cycloheteralkyl group may be attached to the remainder of the molecule via a ring carbon atom or a ring heteroatom.

[0032]"Dialkylamino"or"Monoalkylamino,"by themselves or as part of other substituents, refer to radicals of the formula-NRR and-NHR, respectively, where each R is independently selected from the group consisting of alkyl and cycloalkyl, as defined herein.

Representative examples of dialkylamino groups include, but are not limited to, dimethylamino, methylethylamino, di- (1-methylethyl) amino, (cyclohexyl) (methyl) amino, (cyclohexyl) (ethyl) amino, (cyclohexyl) (propyl) amino and the like. Representative examples of monalkylamino groups include, but are not limited to, methylamino, ethylamino, propylamino, isopropylamino, cyclohexylamino, and the like.

[0033]"Halogen"or"Halo,"by themselves or as part of another substituent, refer to a fluoro, chloro, bromo and/or iodo radical.

[0034]"Haloalkyl,"by itself or as part of another substituent, refers to an alkyl group as defined herein in which one or more of the hydrogen atoms is replaced with a halo group. The term"haloalkyl"is specifically meant to include monohaloalkyls, dihaloalkyls, trihaloalkyls, etc. up to perhaloalkyls. The halo groups substituting a haloalkyl can be the same, or they can be different. For example, the expression"(C,-C2) haloalkyl"includes l-fluoromethyl, 1- fluoro-2-chloroethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 1,1-difluoroethyl, 1, 2-difluoroethyl, 1,1, 1-trifluoroethyl, perfluoroethyl, etc.

[0035]"Haloalkyloxy,"by itself or as part of another substituent, refers to a group of the formula-O-haloalkyl, where haloalkyl is as defined herein.

[0036]"Heteroalkyl,""Heteroalkanyl,""Heteroalkenvl,""Hete roalkynvl," "Heteroalkyldiyl"and"Heteroalkyleno,"by themselves or as part of other substituents, refer to alkyl, alkanyl, alkenyl, alkynyl, alkyldiyl and alkyleno groups, respectively, in which one or more of the carbon atoms (and optionally any associated hydrogen atoms), are each, independently of one another, replaced with the same or different heteroatoms or heteroatomic groups. Typical heteroatoms or heteroatomic groups which can replace the carbon atoms <BR> <BR> <BR> <BR> include, but are not limited to, O, S, N, Si,-NH-,-S (O)-,-S (O) 2-, -S (O) NH-, -S (O) 2NH- and the like and combinations thereof. The heteroatoms or heteroatomic groups may be placed at

any interior position of the alkyl, alkenyl or alkynyl groups. Examples of such heteroalkyl, heteroalkanyl, heteroalkenyl and/or heteroalkynyl groups include-CH2-CH2-O-CH3, -CH2-CH2-NH-CH3,-CH2-CH2-N (CH3)-CH3,-CH2-S-CH2,-CH3,-CH2-CH2-S (O)-CH3, -CH2-CH2-S (O) 2-CH3,-CH=CH-O-CH3,-CH2-CH=N-O-CH3, and-CH2-CH2-O-C=CH. For heteroalkyldiyl and heteroalkyleno groups, the heteratom or heteratomic group can also occupy either or both chain termini. For such groups, no orientation of the group is implied.

[00371"Heteroaryl,"by itself or as part of another substituent, refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring systems, as defined herein. Typical heteroaryl groups include, but are not limited to, groups derived from acridine, p-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, and the like. Preferably, the heteroaryl group comprises from 5 to 20 ring atoms (5- 20 membered heteroaryl), more preferably from 5 to 10 ring atoms (5-10 membered heteroaryl). Preferred heteroaryl groups are those derived from furan, thiophene, pyrrole, benzothiophene, benzofuran, benzimidazole, indole, pyridine, pyrazole, quinoline, imidazole, oxazole, isoxazole and pyrazine.

[0038]"Heteroarylalkyl"by itself or as part of another substituent refers to an acyclic alkyl group in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heteroaryl group. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylakenyl and/or heteroarylalkynyl is used. In preferred embodiments, the heteroarylalkyl group is a 6-21 membered heteroarylalkyl, e. g., the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is (C1-C6) alkyl and the heteroaryl moiety is a 5-15-membered heteroaryl. In particularly preferred embodiments, the heteroarylalkyl is a 6-13 membered heteroarylalkyl, e. g., the alkanyl, alkenyl or alkynyl moiety is (Cl-C3) alkyl and the heteroaryl moiety is a 5-10 membered heteroaryl.

[0039]"Parent Aromatic Ring System"refers to an unsaturated cyclic or polycyclic ring system having a conjugated 71 electron system. Specifically included within the definition of "parent aromatic ring system"are fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, fluorene, indane, indene, phenalene, etc. Typical parent aromatic ring systems include, but are not limited to, aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene and the like.

[0040]"Parent Heteroaromatic Ring System"refers to a parent aromatic ring system in which one or more carbon atoms (and optionally any associated hydrogen atoms) are each independently replaced with the same or different heteroatom. Typical heteroatoms to replace the carbon atoms include, but are not limited to, N, P, O, S, Si, etc. Specifically included within the definition of"parent heteroaromatic ring system"are fused ring systems in which one or more of the rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, benzodioxan, benzofuran, chromane, chromene, indole, indoline, xanthene, etc. Typical parent heteroaromatic ring systems include, but are not limited to, arsindole, carbazole, p-carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene and the like.

[0041]"Pharmaceuticallv acceptable salt"refers to a salt of a compound of the invention which is made with counterions understood in the art to be generally acceptable for pharmaceutical uses and which possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid,

cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3- (4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1, 2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo [2.2. 2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like; or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e. g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, piperidine, dimethylamine, diethylamine and the like. Also included are salts of amino acids such as arginates and the like, and salts of organic acids like glucurmic or galactunoric acids and the like (see, e. g., Berge et al., 1977, J Pharm. Sci. 66: 1-19).

[0042]"Pharmaceutically acceptable vehicle"refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.

[0043]"Protecting group"refers to a group of atoms that, when attached to a reactive functional group in a molecule, mask, reduce or prevent the reactivity of the functional group.

Typically, a protecting group may be selectively removed as desired during the course of a synthesis. Examples of protecting groups can be found in Greene and Wuts, Protective Groups in Organic Chemistry, 3rd Ed., 1999, John Wiley & Sons, NY and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8,1971-1996, John Wiley & Sons, NY Representative amino protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl ("CBZ"), tert-butoxycarbonyl ("Boc"), trimethylsilyl ("TMS"), 2-trimethylsilyl-ethanesulfonyl ("SES"), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl ("FMOC"), nitro-veratryloxycarbonyl ("NVOC") and the like. Representative hydroxyl protecting groups include, but are not limited to, those where the hydroxyl group is either acylated (e. g., methyl and ethyl esters, acetate or propionate groups or glycol esters) or alkylated such as benzyl and

trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers (e. g. , TMS or TIPPS groups) and allyl ethers.

[0044]"Prodrug"refers to a derivative of an active compound (drug) that undergoes a transformation under the conditions of use, such as within the body, to release an active drug.

Prodrugs are frequently, but not necessarily, pharmacologically inactive until converted into the active drug. Prodrugs are typically obtained by masking a functional group in the drug believed to be in part required for activity with a progroup (defined below) to form a promoiety which undergoes a transformation, such as cleavage, under the specified conditions of use to release the functional group, and hence the active drug. The cleavage of the promoiety may proceed spontaneously, such as by way of a hydrolysis reaction, or it may be catalyzed or induced by another agent, such as by an enzyme, by light, by acid, or by a change of or exposure to a physical or environmental parameter, such as a change of temperature. The agent may be endogenous to the conditions of use, such as an enzyme present in the cells to which the prodrug is administered or the acidic conditions of the stomach, or it may be supplied exogenously.

[0045] A wide variety of progroups, as well as the resultant promoieties, suitable for masking functional groups in active compounds to yield prodrugs are well-known in the art.

For example, a hydroxyl functional group may be masked as a sulfonate, ester or carbonate promoiety, which may be hydrolyzed in vitro to provide the hydroxyl group. An amino functional group may be masked as an amide, imine, phosphinyl, phosphonyl, phosphoryl or sulfenyl promoiety, which may be hydrolyzed in vivo to provide the amino group. A carboxyl group may be masked as an ester (including silyl esters and thioesters), amide or hydrazide promoiety, which may be hydrolyzed in vivo to provide the carboxyl group. Other specific examples of suitable progroups and their respective promoieties will be apparent to those of skill in the art.

[0046]"Progroup"refers to a type of protecting group that, when used to mask a functional group within an active drug to form a promoiety, converts the drug into a prodrug.

Progroups are typically attached to the functional group of the drug via bonds that are cleavable under specified conditions of use. Thus, a progroup is that portion of a promoiety that cleaves to release the functional group under the specified conditions of use. As a specific

example, an amide promoiety of the formula-NH-C (O) CH3 comprises the progroup -C(O) CH3.

[0047]"Substituted,"when used to modify a specified group or radical, means that one or more hydrogen atoms of the specified group or radical are each, independently of one another, replaced with the same or different substituent (s). Substituent groups useful for substituting saturated carbon atoms in the specified group or radical include, but are not limited to-Ra, halo,-0', =O,-ORb,-SRb,-S-, =S,-NRCRc, =NRb, =N-ORb, trihalomethyl,-CF3, -CN, -OCN, -SCN, -NO, -NO2, =N2, -N3, -S(O)2Rb, -S(O)2O-, -S(O)2ORb, -OS(O)2Rb, -OS(O)2O-, -OS(O)2ORb, -P(O)(O-)2, -P(O)(ORb)(O-), -P(O)(ORb)(ORb), -C(O)Rb, -C(S)Rb, -C(NRb)Rb, -C(O)O-, -C(O)ORb, -C(S)ORb, -C(O)NRcRc, -C(NRb)NRcRc, -OC(O)Rb, -OC (S) Rb,-OC (O) O-,-OC (O) ORb,-OC (S) ORb,-NRbC (O) Rb,-NRbC (S) Rb,-NRbC (O) O, -NRbC(O)ORb, -NRbC (S) ORb,-NRbC (O) NRcRc, -NRbC(NRb)Rb and -NRbC(NRb)NRcRc, where Ra is selected from the group consisting of alkyl, cycloalkyl, heteroalkyl, cycloheteroalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl ; each Rb is independently hydrogen or Ra; and each Rc is independently Rb or alternatively, the two RCs are taken together with the nitrogen atom to which they are bonded form a 5-, 6-or 7-membered cycloheteroalkyl which may optionally include from 1 to 4 of the same or different additional heteroatoms selected from the group consisting of O, N and S. As specific examples,-NRCRc is meant to include-NH2,-NH-alkyl, N-pyrrolidinyl and N-morpholinyl.

[0048] Similarly, substituent groups useful for substituting unsaturated carbon atoms in the specified group or radical include, but are not limited to,-Ra, halo,-O-,-ORb,-SRb,-S-, - NR'R', trihalomethyl,-CF3,-CN,-OCN,-SCN,-NO,-NO2,-N3,-S (O) 2Rb,-S (O) 20-, - S(O)2ORb, -OS(O)2Rb, -OS(O)2O-, -OS(O)ORb, -P(O)(O-)2, -P(O)(ORb)(O-), -P(O)(ORb)(ORb), -C(O)Rb, -C(S)Rb, -C(NRb)Rb, -C(O)O-, -C(O)ORb, -C (S) OR, -C(O)NRcRc, -C(NRb)NRcRc, -OC(O)Rb, -OC (S) Rb,-OC (O) O-, -OC (O) ORb,-OC (S) OR -NRbC(O)Rb, -NRbC (S) Rb,-NRbC (O) O-,-NRbC (O) ORb,-NRbC (S) ORb, -NRbC(O)NRcRc, -NRbC(NRb)Rb and -NRbC(NRb)NRcRc, where Ra, Rb and Rc are as previously defined.

[0049] Substituent groups useful for substituting nitrogen atoms in heteroalkyl and cycloheteroalkyl groups include, but are not limited to,-R,-0-,-OR b,-SR b,-S-,-NRcRc, trihalomethyl, -CF3, -CN, -NO, -NO2, -S (O) 2Rb,-S (O) 20-,-S (O) 2ORb,-OS (O) 2Rb,-OS (O) 20-, -OS(O)ORb, -P(O)(O-)2, -P(O)(ORb)(O-), -P(O)(ORb)(ORb), -C(O)Rb, -C(S)Rb, -C(NRb)Rb,

-C (O) ORb,-C (S) ORb,-C (O) NRR,-C (NRb) NRCRC,-OC (O) Rv,-OC (S) Rb,-OC (O) ORb, - OC (S) ORb,-NRbC (O) Rb,-NRbC (S) Rb,-NRbC (O) ORb,-NRbC (S) ORb,-NRbC (O) NRCRC, -NRbC (NRb) Rb and-NRbC (NRb) NRCRC, where Ra, R b and Rc are as previously defined.

[0050] Substituent groups from the above lists useful for substituting other specified groups or atoms will be apparent to those of skill in the art.

[0051] The substituents used to substitute a specified group can be further substituted, typically with one or more of the same or different groups selected from the various groups specified above.

[0052]"Sulfamoyl,"by itself or as part of another substituent, refers to a radical of the formula-S (0) 2NR'R", where R'and R"are each, independently of one another, selected from the group consisting of hydrogen, alkyl and cycloalkyl as defined herein, or alternatively, R' and R", taken together with the nitrogen atom to which they are bonded, form a 5-, 6-or 7- membered cycloheteroalkyl ring as defined herein, which may optionally include from 1 to 4 of the same or different additional heteroatoms selected from the group consisting of O, S and N.

[0053] The compounds of the present invention may be used to inhibit or reduce the HCV replication and/or proliferation. In these contexts, inhibition and reduction of HCV proliferation refers to a lower level of the measured activity relative to a control experiment in which the cells or the subjects are not treated with the test compound. In particular aspects, the inhibition or reduction in the measured activity is at least a 10% reduction or inhibition.

One of skill in the art will appreciate that reduction or inhibition of the measured activity of at least 20%, 50%, 75%, 90% or 100%, or any number in between, may be preferred for particular applications.

II. THE COMPOUNDS [0054] The invention provides novel isoxazoloanthrone compounds, and isoxazoloanthome compounds that are potent inhibitors of HCV replication and/or proliferation. In one aspect, the compounds of the invention have the formula :

wherein""5$ and t are independently selected to be a single bond or a double bond; [0055] Xl and X2 are independently selected from the group consisting of O, N, NRg, S, SO, SO2, and CR9Rlo wherein R8 is H, lower alkyl, cycloalky, aryl, alkylcarbonyl, or arylcarbonyl, and Rg and RIO are independently selected from the group consisting of H and lower alkyl ; and [0056] Ri, R2, R3, R4, R5, R6, and R7 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, cyano, nitro, amino, alkoxyl, aryloxyl, aralkoxyl, alkylcarbamido, arylcarbamido, dialkylcarbamido, diarylcarbamido, alkylarylcarbamido, alkylthiocarbamido, arylthiocarbamido, dialkylthiocarbamido, diarylthiocarbamido, alkylarylthiocarbamidb, alkylamino, arylamino, dialkylamino, diarylamino, arylalkylamino, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, dialkylaminocarbonyl, diarylaminocarbonyl, arylalkylamino-carbonyl, alkylcarbonyloxy, arylcarbonyloxy, carboxyl, alkoxycarbonyl, aryloxycarbonyl, sulfo, alkylsulfonylamido, arylsulfonylarnido, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl and heteroaryl; [0057] with the proviso that when # and # are both double bonds, Xi is N, X2 is O, and R2, R4, R5, R6, and R7 are H, then (a) if R3 is aziridine, then R, cannot be H, Br, Cl, or Me; (b) if R3 is Br, then R, cannot be Me or OH; and (c) both R3 and Rl cannot be H, Br, Cl, OPh, or p-chlorophenoxy.

[0058] Exemplary compounds of the invention are provided below. Also included in the invention are the various regioisomers of the compounds described herein.

[0059] Those of skill in the art will appreciate that the compounds of the invention described herein may include functional groups that can be masked with progroups to create prodrugs. Such prodrugs are usually, but need not be, pharmacologically inactive until converted into their active drug form. In the prodrugs of the invention, any available functional moiety may be masked with a progroup to yield a prodrug. Myriad progroups suitable for masking such functional groups to yield promoieties that are cleavable under the desired conditions of use are known in the art. Specific examples are described supra.

III. METHODS OF SYNTHESIS [0060] The compounds of the invention comprise isoxazoloanthrones, as described above. The compounds can be obtained from commercial sources, such as Aldrich Chemical Co. (Milwaukee, Wis. ), Sigma Chemical Co. (St. Louis, Mo. ), or Maybridge (Cornwall, England), or the compounds can be synthesized. The compounds of the present invention, and other related compounds having different subtituents identified by any of the methods described above can be synthesized using techniques and materials known to those of skill in the art, such as described, for example, in March, ADVANCED ORGANIC CHEMISTRY 4th Ed. , (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTY 3rd Ed. , Vols.

A and B (Plenum 1992), and Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 2nd Ed. (Wiley 1991). Starting materials useful for preparing compounds of the invention and intermediates thereof are commercially available or can be prepared by well- known synthetic methods (see, e. g., Harrison et al.,"Compendium of Synthetic Organic Methods", Vols. 1-8 (John Wiley and Sons, 1971-1996) ;"Beilstein Handbook of Organic Chemistry, "Beilstein Institute of Organic Chemistry, Frankfurt, Germany; Feiser et al., "Reagents for Organic Synthesis, "Volumes 1-21, Wiley Interscience; Trost et al., "Comprehensive Organic Synthesis, "Pergamon Press, 1991;"Theilheimer's Synthetic Methods of Organic Chemistry, "Volumes 1-45, Karger, 1991; March, "Advanced Organic Chemistry, "Wiley Interscience, 1991 ; Larock"Comprehensive Organic Transformations," VCH Publishers, 1989; Paquette, "Encyclopedia of Reagents for Organic Synthesis,"3d Edition, John Wiley & Sons, 1995). Other methods for synthesis of the compounds described herein and/or starting materials are either described in the art or will be readily apparent to the skilled artisan. Alternatives to the reagents and/or protecting groups may be found in the references provided above and in other compendiums well known to the skilled artisan.

Guidance for selecting suitable protecting groups can be found, for example, in Greene & Wuts, "Protective Groups in Organic Synthesis, "Wiley Interscience, 1999. Accordingly, the synthetic methods and strategy presented herein are illustrative rather than comprehensive.

Thus, for example, Compound 8 above can be synthesized using the reaction scheme shown below:

: o-N o iso NO OH NaN-0 N 0 O-N 0 12 or (COCI) 2 I % H I O O H N ' 0 0 0 0 H2N 1 ? 8 0 0 0 JO 0 H. N-Y g [0061] The procedures described herein for synthesizing the compounds of the invention may include one or more steps of protection and deprotection (e. g. , the formation and removal of acetal groups). In addition, the synthetic procedures disclosed below can include various purifications, such as column chromatography, flash chromatography, thin-layer chromatography (TLC), recrystallization, distillation, high-pressure liquid chromatography (HPLC) and the like. Also, various techniques well known in the chemical arts for the identification and quantification of chemical reaction products, such as proton and carbon-13 nuclear magnetic resonance ('H and 13C NMR), infrared and ultraviolet spectroscopy (IR and UV), X-ray crystallography, elemental analysis (EA), HPLC and mass spectroscopy (MS) can be used as well. Methods of protection and deprotection, purification and identification and quantification are well known in the chemical arts.

IV. ASSAYS FOR MODULATION OF HCV [0062] The compounds of the invention are potent inhibitors of HCV replication and/or proliferation. The activity of the compounds of the invention can be confirmed in in vitro assays suitable for measuring inhibition of viral or retroviral replication and/or proliferation.

The assays may investigate any parameter that is directly or indirectly under the influence of HCV, including, but not limited to, protein-RNA binding, translation, transcription, genome replication, protein processing, viral particle formation, infectivity, viral transduction, etc.

Such assays are well-known in the art. Regardless of the parameter being investigated, in one embodiment, to examine the extent of inhibition, samples, cells, tissues, etc. comprising an HCV replicon or HCV RNA are treated with a potential inhibitory compound (test compound) and the value for the parameter compared to control cells (untreated or treated with a vehicle or other placebo). Control samples are assigned a relative activity value of 100%. Inhibition

is achieved when the activity value of the test compound relative to the control is about 90%, preferably 50%, and more preferably 25-0%.

[0063] Alternatively, the extent of inhibition may be determined based upon the IC50 of the compound in the particular assay, as will be described in more detail, below.

[0064] In one embodiment, the inhibitory activity of the compounds can be confirmed in a replicon assay that assesses the ability of a test compound to block or inhibit HCV replication in replicon cells. One example of a suitable replicon assay is the liver cell-line Huh 7-based replicon assay described in Lohmann et al. , 1999, Science 285: 110-113. A specific example of this replicon assay which utilizes luciferase translation is provided in the Examples Section. In one embodiment of this assay, the amount of test compound that yields a 50% reduction in translation as compared to a control cell (IC5o) may be determined.

[0065] Alternatively, the inhibitory activity of the compounds can be confirmed using a quantitative Western immunoblot assay utilizing antibodies specific for HCV non-structural proteins, such as NS3, NS4A NS5A and NS5B. In one embodiment of this assay, replicon cells are treated with varying concentrations of test compound to determine the concentration of test compound that yields a 50% reduction in the amount of a non-structural protein produced as compared to a control sample (IC50). A single non-structural protein may be quantified or multiple non-structural proteins may be quantified. Antibodies suitable for carrying out such immunoblot assays are available commercially (e. g. , from BIODESIGN International, Saco, ME).

[0066] Alternatively, the inhibitory activity of the compounds may be confirmed in an HCV infection assay, such as the HCV infection assay described in Fournier et al., 1998, J.

Gen. Virol. 79 (10): 2367: 2374, the disclosure of which is incorporated herein by reference. In one embodiment of this assay, the amount of test compound that yields a 50% reduction in HCV replication or proliferation as compared to a control cell (IC50) may be determined. The extent of HCV replication may be determined by quantifying the amount of HCV RNA present in HCV infected cells. A specific method for carrying out such an assay is provided in the Examples section.

[0067] As yet another example, the inhibitory activity of the compounds can be confirmed using an assay that quantifies the amount of HCV RNA transcribed in treated replicon cells using, for example, a Taqman assay (Roche Molecular, Alameda, CA). In one

embodiment of this assay, the amount of test compound that yields a 50% reduction in transcription of one or more HCV RNAs as compared to a control sample (IC50) may be determined.

[0068] Regardless of the assay used, active compounds are generally those which exhibit IC50s in the particular assay in the range of about 1 mM or less. Compounds which exhibit lower IC50s, for example, in the range of about 100 pM, 10 ßM, 1 pM, 100 nM, 10 nM, 1 nM, or even lower, are particularly useful for as therapeutics or prophylactics to treat or prevent HCV infections.

V. USES AND ADMINISTRATION [0069] Owing to their ability to inhibit HCV replication, the compounds of the invention and/or compositions thereof can be used in a variety of contexts. For example, the compounds of the invention can be used as controls in in vitro assays to identify additional more or less potent anti HCV compounds. As another example, the compounds of the invention and/or compositions thereof can be used as preservatives or disinfectants in clinical settings to prevent medical instruments and supplies from becoming infected with HCV virus. When used in this context, the compound of the invention and/or composition thereof may be applied to the instrument to be disinfected at a concentration that is a multiple of the measured IC50 for the compound.

[0070] In a specific embodiment, the compounds and/or compositions can be used to "disinfect"organs for transplantation. For example, a liver or portion thereof being prepared for transplantation can be perfused with a solution comprising an inhibitory compound of the invention prior to implanting the organ into the recipient. This method has proven successful with lamuvidine (3TC, Epivir, Epivir-HB@) for reducing the incidence of hepatitis B virus (HBV) infection following liver transplant surgery/therapy. Quite interestingly, it has been found that such perfusion therapy not only protects a liver recipient free of HBV infection (HBV-) from contracting HBV from a liver received from an HBV+ donor, but it also protects a liver from an HBV-donor transplanted into an HBV+ recipient from attack by HBV. The compounds of the invention may be used in a similar manner prior to organ or liver transplantation.

[0071] The compounds of the invention and/or compositions thereof find particular use in the treatment and/or prevention of HCV infections in animals and humans. When used in this context, the compounds may be administered per se, but are typically formulated and administered in the form of a pharmaceutical composition. The exact composition will depend upon, among other things, the method of administration and will apparent to those of skill in the art. A wide variety of suitable pharmaceutical compositions are described, for example, in Remington's Pharmaceutical Sciences, 20th ed., 2001).

[0072] Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the active compound suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers.

Lozenge forms can comprise the active ingredient in a flavor, e. g. , sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.

[0073] The compound of choice, alone or in combination with other suitable components, can be made into aerosol formulations (i. e. , they can be"nebulized") to be administered via inhalation. Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

[0074] Suitable formulations for rectal administration include, for example, suppositories, which consist of the packaged nucleic acid with a suppository base. Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the compound of choice with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.

[0075] Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the practice of this invention, compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. Parenteral administration, oral administration, subcutaneous administration and intravenous administration are the preferred methods of administration. A specific example of a suitable solution formulation may comprise from about 0.5-100 mg/ml compound and about 1000 mg/ml propylene glycol in water. Another specific example of a suitable solution formulation may comprise from about 0.5-100 mg/ml compound and from about 800-1000 mg/ml polyethylene glycol 400 (PEG 400) in water.

[0076] A specific example of a suitable suspension formulation may include from about 0.5-30 mg/ml compound and one or more excipents selected from the group consisting of : about 200 mg/ml ethanol, about 1000 mg/ml vegetable oil (e. g., corn oil), about 600-1000 mg/ml fruit juice (e. g., grapefruit juice), about 400-800 mg/ml milk, about 0.1 mg/ml carboxymethylcellulose (or microcrystalline cellulose), about 0.5 mg/ml benzyl alcohol (or a combination of benzyl alcohol and benzalkonium chloride) and about 40-50 mM buffer, pH 7 (e. g. , phosphate buffer, acetate buffer or citrate buffer or, alternatively 5% dextrose may be used in place of the buffer) in water.

[0077] A specific example of a suitable liposome suspension formulation may comprise from about 0.5-30 mg/ml compound, about 100-200 mg/ml lecithin (or other phospholipid or mixture of phospholipids) and optionally about 5 mg/ml cholesterol in water.

[0078] The formulations of compounds can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials. Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

[0079] The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing

discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. The composition can, if desired, also contain other compatible therapeutic agents, discussed in more detail, below.

[0080] In therapeutic use for the treatment of HCV infection, the compounds utilized in the pharmaceutical method of the invention are administered to patients diagnosed with HCV infection at dosage levels suitable to achieve therapeutic benefit. By therapeutic benefit is meant that the administration of compound leads to a beneficial effect in the patient over time.

For example, therapeutic benefit is achieved when the HCV titer or load in the patient is either reduced or stops increasing. Therapeutic benefit is also achieved if the administration of compound slows or halts altogether the onset of the organ damage that or other adverse symptoms typically accompany HCV infections, regardless of the HCV titer or load in the patient.

[0081] The compounds of the invention and/or compositions thereof may also be administered prophylactically in patients who are at risk of developing HCV infection, or who have been exposed to HCV, to prevent the development of HCV infection. For example, the compounds of the invention and/or compositions thereof may be administered to hospital workers accidentally stuck with needles while working with HCV patients to lower the risk of, or avoid altogether, developing an HCV infection.

[0082] Initial dosages suitable for administration to humans may be determined from in vitro assays or animal models. For example, an initial dosage may be formulated to achieve a serum concentration that includes the ICso of the particular compound being administered, as measured in an in vitro assay. Alternatively, an initial dosage for humans may be based upon dosages found to be effective in animal models of HCV infection. Exemplary suitable model systems are described, for example, in Muchmore, 2001, Immunol. Rev. 183: 86-93 and Lanford & Bigger, 2002, Virology, 293: 1-9, and the referenced cited therein. As one example, the initial dosage may be in the range of about 0. 01 mg/kg/day to about 200 mg/kg/day, or about 0.1 mg/kg/day to about 100 mg/kg/day, or about 1 mg/kg/day to about 50 mg/kg/day, or about 10 mg/kg/day to about 50 mg/kg/day, can also be used. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration

of a particular compound in a particular patient. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

VI. COMBINATION THERAPY [0083] In certain embodiments of the present invention, the compounds of the invention and/or compositions thereof can be used in combination therapy with at least one other therapeutic agent. A compound of the invention and/or composition thereof and the therapeutic agent can act additively or, more preferably, synergistically. The compound of the invention and/or a composition thereof may be administered concurrently with the administration of the other therapeutic agent (s), or it may be administered prior to or subsequent to administration of the other therapeutic agent (s).

[0084] In one embodiment, the compounds of the invention and/or compositions thereof are used in combination therapy with other antiviral agents or other therapies known to be effective in the treatment or prevention of HCV. As a specific example, the compounds of the invention and/or compositions thereof may be used in combination with known antivirals, such as ribavirin (see, e. g., US Patent No. 4,530, 901). As another specific example, the compounds of the invention and/or compositions thereof may also be administered in combination with one or more of the compounds described in any of the following: U. S.

Patent No. 6,143, 715; U. S. Patent No. 6,323, 180; U. S. Patent No. 6,329, 379; U. S. Patent No.

6,329, 417; U. S. Patent No. 6,410, 531; U. S. Patent No. 6,420, 380; and U. S. Patent No.

6,448, 281.

[0085] Yet another specific example, the compounds of the invention and/or compositions thereof may be used in combination with interferons such as a-interferon, P-interferon and/or y-interferon. The interferons may be unmodified, or may be modified with moieties such as polyethylene glycol (pegylated interferons). Many suitable unpegylated and pegylated interferons are available commercially, and include, by way of example and not limitation, recombinant interferon alpha-2b such as Intron-A interferon available from Schering Corporation, Kenilworth, N. J. , recombinant interferon alpha-2a such

as Roferon interferon available from Hoffmann-La Roche, Nutley, N. JU. , recombinant interferon alpha-2C such as Berofor alpha 2 interferon available from Boehringer Ingelheim Pharmaceutical, Inc. , Ridgefield, Conn. , interferon alpha-nl, a purified blend of natural alpha interferons such as Sumiferon available from Sumitomo, Japan or as Wellferon interferon alpha-nl (INS) available from the Glaxo-Wellcome Ltd. , London, Great Britain, or a consensus alpha interferon such as those described in U. S. Pat. Nos. 4,897, 471 and 4,695, 623 (especially Examples 7,8 or 9 thereof) and the specific product available from Amgen, Inc., Newbury Park, Calif., or interferon alpha-n3 a mixture of natural alpha interferons made by Interferon Sciences and available from the Purdue Frederick Co. , Norwalk, Conn. , under the Alferon Tradename, pegylated interferon-2b available from Schering Corporation, Kenilworth, N. J. under the tradename PEG-Intron A and pegylated interferon-2a available from Hoffman- LaRoche, Nutley, N. J. under the tradename Pegasys.

[0086] As yet another specific example, the compounds of the invention and/or compositions thereof may be administered in combination with both ribovirin and an interferon.

VII. EXAMPLES [0087] The following examples are provided by way of illustration only and not by way of limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results 1. 1 Exemplary Compounds of the Invention Inhibit HCV Translation Or Replication 1. 1. 1 Replicon Assay [0088] The inhibitory activity of certain exemplary compounds of the invention was confirmed using an HCV replicon assay. The HCV replicon can include such features as the HCV 5'untranslated region including the HCV IRES, the HCV 3'untranslated region, selected HCV genes encoding HCV polypeptides, selectable markers, and a reporter gene such as luciferase, GFP, etc. In the assay, actively dividing 5-2 Luc replicon-comprising cells (obtained from Rolf Bartenschlager ; see Lohmann et al., 1999, Science 285: 110-113) were seeded at a density of between about 5,000 and 7,500 cells/well onto 96 well plates (about 90 ul of cells per well) and incubated at 37 °C and 5% C02 for 24 hours. Then, the test compound (in a volume of about 10 ul) was added to the wells at various concentrations and

the cells were incubated for an additional 24 hours before luciferase assay. The media was aspirated from each well and Bright-Glo (Promega, Madison, WI) luciferase assay reagents were added to each well according to the manufacturer's instructions. Briefly, the Bright-Glo reagent was diluted 1: 1 with PBS and 100 ul of diluted reagent was added to each well. After 5 min of incubation at room temperature, luciferin emission was quantified with a luminometer. In this assay, the amount of test compound that yielded a 50% reduction in luciferase emission (IC50) was determined.

1.1. 2 Western Blot Assay [0089] Certain exemplary compounds of the invention were also tested for their ability to inhibit HCV replication using a quantitative Western blot analysis with antibodies specific for the HCV nonstructural protein NS5A. Actively dividing 9-13 replicon cells were seeded into 6-well plates at a density of 1X105 cells/well in a volume of 2 ml/well and incubated at 37°C and 5% C02 for 24 hours. Various concentrations of test compounds (in a volume of 10 ul) were added to the wells and the cells incubated for another 48 hours. Protein samples were prepared from the cultured cells, resolved on a SDS-PAGE gel and transferred to a nitrocellulose membrane. The membrane was blocked with 5% non-fat milk in PBS for 1 hour at room temperature. Primary antibody (anti NS5A antibody; BIODESIGN International, Saco, ME) incubation was performed for 1 hour at room temperature, after which the membrane was washed 3 times (for 15 min per time) with PBST (PBS plus 0.1% Tween 20).

Horseradish peroxidase conjugated secondary antibody incubation was performed for 1 hour at room temperature and the membrane was washed 3 times (for 15 min per time) with PBST.

The membrane was then soaked in substrate solution (Pierce) and exposed to a film or quantified using an imager. In this assay, the amount of test compound that yielded a 50% reduction in the amount of NS5A protein translated as compared to a control sample (ICso) was determined.

[0090] Compounds 2 and 3 had an ICso in the Replicon luciferase emission assay of 0.8 , uM and 9999 uM.

1.1. 3 Luciferase Counter Screen

[0091] A counter screen was used to identify non-specific inhibitors of the luciferase reporter gene. In the counter screen, a cell line carrying a construct such as a CMV-driven luciferase gene was used to identify compounds that inhibit the reporter gene, and not HCV.

In these CMV-Luc cells, the DNA construct, which comprises a luciferase gene downstream of a CMV promoter, is permanently integrated into the chromosome of Huh7 cells. For the counter screen, actively dividing CMV-Luc cells were seeded at a density of 5000-7500 cells/well in a volume of 90 ul/well into 96 well plate (s). The cells were then incubated at 37°C and 5% C02 for 24 hours. Various concentrations of test compounds (in a volume of 10 ul) were added to the wells and the cells were incubated for another 24 hours. Media was aspirated from each well and Bright-Glo (Pharmacia) luciferase assay reagents were added to each well according to the manufacturer's manual. Luciferin counts were taken using a luminometer.

1.1. 4 PCR Assay [0092] A TaqMan RT-PCR assay (Roche Molecular Systems, Pleasanton, CA) was used to analyze HCV RNA copy numbers, which confirmed that the viral genome of HCV is not being replicated. Actively dividing 9-13 replicon cells were seeded at a density of 3 x 104 cells/well in a volume of 1 ml/well into 24-well plates. The cells were then incubated at 37° C and 5% C02 for 24 hours. Various concentrations of test compounds (in a volume of 10 ul) were added to the wells and the cells were incubated for an additional 24-48 hours. Media was removed by aspiration and RNA samples prepared from each well. TaqMan one step RT-PCR (Roche Molecular Systems, Alameda, CA) was performed using the freshly prepared RNA samples according to the manufacturer's manual and analyzed on an ABI Prism 7700 Sequence Detector (Applied Biosystems). The ratio of HCV RNA to cellular GAPDH RNA was used as in indication of specificity of HCV inhibition to confirm that the viral genome was not replicated.

1.2 The Compounds Are Non-Toxic In Cellular and Animal Models 1.2. 1 Cytotoxicity [0093] Compound 2 was tested in a cytotoxicity assay with liver cells including an HCV replicon (5-2 Luc cells, 9-13 cells or Huh-7 cells). In the assay, cells were seeded onto 96- well plates (approx. 7500 cells/well in a volume of 90 RI) and grown for 24 hr at 37°C. On

day 2, various concentrations of test compound (in a volume of 10 1) were added to the wells and the cells were grown for an additional 24 hr at 37°C. On day 3, an ATP-dependent R- Luciferase assay (Cell Titer Glo assay) was performed to determine the number of viable cells.

The compound had ICso of 9999 I1M, demonstrating that the compound is well-tolerated, as well.

[0094] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

[0095] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.